|10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer|
FC Hamdy, JL Donovan, JA Lane, M Mason, C Metcalfe, P Holding, ...
New England Journal of Medicine 375 (15), 1415-1424, 2016
|Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer|
JL Donovan, FC Hamdy, JA Lane, M Mason, C Metcalfe, E Walsh, ...
New England Journal of Medicine 375 (15), 1425-1437, 2016
|The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer|
JC Smith, S Bennett, LM Evans, HG Kynaston, M Parmar, MD Mason, ...
The Journal of Clinical Endocrinology & Metabolism 86 (9), 4261-4267, 2001
|An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer|
G Van Andel, A Bottomley, SD Fosså, F Efficace, C Coens, S Guerif, ...
European journal of cancer 44 (16), 2418-2424, 2008
|Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes|
JP Webber, LK Spary, AJ Sanders, R Chowdhury, WG Jiang, R Steadman, ...
Oncogene 34 (3), 290-302, 2015
|Intravesical bacillus Calmette‐Guerin is superior to mitomycin C in reducing tumour recurrence in high‐risk superficial bladder cancer: a meta‐analysis of randomized trials|
MD Shelley, TJ Wilt, J Court, B Coles, H Kynaston, MD Mason
BJU international 93 (4), 485-490, 2004
|A systematic review of intravesical bacillus Calmette‐Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer|
MD Shelley, H Kynaston, J Court, TJ Wilt, B Coles, K Burgon, MD Mason
BJU international 88 (3), 209-216, 2001
|Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial|
CC Parker, NW Clarke, AD Cook, HG Kynaston, PM Petersen, C Catton, ...
The Lancet 396 (10260), 1413-1421, 2020
|Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses|
MD Shelley, MD Mason, H Kynaston
Cancer treatment reviews 36 (3), 195-205, 2010
|Human monocyte isolation methods influence cytokine production from in vitro generated dendritic cells|
E Elkord, PE Williams, H Kynaston, AW Rowbottom
Immunology 114 (2), 204-212, 2005
|The prevalence and predictors of psychological distress in patients with early localized prostate cancer|
JI Bisson, HL Chubb, S Bennett, M Mason, D Jones, H Kynaston
BJU international 90 (1), 56-61, 2002
|Court J, Wilt TJ, Coles B, Burgon K, et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and …|
MD Shelley, H Kynaston
BJU Int 88 (3), 209-16, 2001
|Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of …|
C Parker, MR Sydes, C Catton, H Kynaston, J Logue, C Murphy, ...
BJU international 99 (6), 1376-1379, 2007
|Intravesical gemcitabine therapy for non‐muscle invasive bladder cancer (NMIBC): a systematic review|
MD Shelley, G Jones, A Cleves, TJ Wilt, MD Mason, HG Kynaston
BJU international 109 (4), 496-505, 2012
|ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common …|
C Coyle, FH Cafferty, S Rowley, M MacKenzie, L Berkman, S Gupta, ...
Contemporary clinical trials 51, 56-64, 2016
|RADICALS (radiotherapy and androgen deprivation in combination after local surgery)|
C Parker, N Clarke, J Logue, H Payne, C Catton, H Kynaston, C Murphy, ...
Clinical Oncology 19 (3), 167-171, 2007
|Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4|
L Ye, H Kynaston, WG Jiang
Molecular cancer research 6 (10), 1594-1606, 2008
|Intravesical bacillus Calmette‐Guerin in Ta and T1 bladder cancer|
M Shelley, JB Court, H Kynaston, TJ Wilt, R Fish, M Mason, ...
Cochrane Database of Systematic Reviews 2010 (3), 1996
|Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to …|
DE Neal, C Metcalfe, JL Donovan, JA Lane, M Davis, GJ Young, ...
European urology 77 (3), 320-330, 2020
|A role for STEAP2 in prostate cancer progression|
H Whiteland, S Spencer-Harty, C Morgan, H Kynaston, DH Thomas, ...
Clinical & experimental metastasis 31, 909-920, 2014